Aragen Life Sciences Revenue, Valuation, Funding & Investors

Aragen Life Sciences is valued at $1.4B as of January 2025, a 7.8x multiple on its last reported $179M revenue.

Last Aragen Life Sciences valuation

$1.4B

Undisclosed stage · Jan 2025

Last Aragen Life Sciences funding round

$100M

Undisclosed stage · Jan 2025

Aragen Life Sciences revenue

$179M

Undisclosed stage · Jan 2025

Key investors in Aragen Life Sciences

  • ChrysCapital
  • Quadria Capital
  • Avendus Capital
  • SBI Life Insurance

Aragen Life Sciences Overview

About Aragen Life Sciences

Aragen Life Sciences is a Hyderabad-based discovery and development organization providing integrated drug discovery, clinical development, and contract manufacturing services across small molecules and biologics for global pharma clients. Formerly GVK Biosciences, it employs 2,400 scientists in facilities totaling 1.2 million square feet in India and the United States. Founded in 2001, Aragen serves top pharmaceutical firms with capabilities in medicinal chemistry, ADME, and GMP manufacturing.


Founded

2001

HQ

IndiaHyderabad

Website

aragen.com

Status

Privately held

Customer focus

B2B

Revenue model

Services

Revenue

$179M (Jan 2025)

Valuation

$1.4B (Jan 2025)

Aragen Life Sciences Valuation

Aragen Life Sciences is currently valued at $1.4B, based on its undisclosed-stage round in January 2025.

The $100M round was led by Quadria Capital.

Aragen Life Sciences valuation by funding round

Aragen Life Sciences valuation by funding round
DateStageValuationRevenue Multiple
Jan 2025Undisclosed stage$1.4B7.8x

Aragen Life Sciences Revenue

Aragen Life Sciences' latest recorded revenue is $179M, as of its undisclosed-stage round in January 2025. At a $1.4B valuation, that implies a 7.8x revenue multiple.

Aragen Life Sciences revenue by funding round

Aragen Life Sciences revenue and valuation multiple by funding round
DateRevenue *ValuationRevenue MultipleStage
Jan 2025$179M$1.4B7.8xUndisclosed stage

* Revenue (or ARR) figures are the values recorded alongside each funding round. Typically run-rate revenue at the time of the deal, or a reported LTM (last 12 months) revenue.

Aragen Life Sciences Funding History

Aragen Life Sciences has raised a total of $100M across 1 funding round, plus 2 secondary share sales.

Aragen Life Sciences funding rounds

Aragen Life Sciences funding rounds
DateStageInvestorsRaisedValuationDeal Summary
Aug 2025SecondaryAvendus Capital (lead); SBI Life Insurance (lead)$34M-Aragen Life Sciences is a contract research development and manufacturing organization (CRDO) providing outsourcing services for drug discovery, clinical trials, and manufacturing to over 450 clients globally, including major biotech and pharmaceutical companies. The company operates both small molecule and biologics (large molecule) platforms following the rebranding of GVK BIO as Aragen Life Sciences. Aragen was valued at approximately $1.37 billion (Rs 12,000 crore) according to available transaction data reported by VCCircle. The company generated revenue of Rs 1,657.6 crore in fiscal year 2023-24 and Rs 1,200 crore in fiscal year 2021, serving primarily Western markets which accounted for over 95% of revenue. Aragen is backed by Goldman Sachs' private equity arm, which invested approximately Rs 235.8 crore in 2021, and has also received investment from Quadria Capital and other institutional investors.
Jan 2025Undisclosed stageQuadria Capital (lead)$100M$1.4BAragen Life Sciences, a Hyderabad-based contract research, development, and manufacturing organization (CRDMO), provides drug discovery, development, and manufacturing services for small and large molecules to pharmaceutical, biotech, and agrochemical companies. It operates eight facilities across India (Hyderabad, Bengaluru, Pune, Visakhapatnam), the US (Morgan Hill, California), and the Netherlands, employing over 4,500 people including 450+ PhDs, and serves more than 450 clients, including 15 of the top 20 global pharma companies and seven of the top 10. On January 13, 2025, Quadria Capital invested $100 million (about Rs 860 crore) in a pre-IPO round, acquiring a minority stake of approximately 8-10% at a $1.4 billion valuation, primarily through fresh capital infusion with a small portion from existing shareholders like Goldman Sachs. The funds will expand infrastructure, capabilities in oligonucleotides, peptides, antibody-drug conjugates, biologics, and adopt AI/ML technologies to meet outsourcing demand from US and Europe innovators amid supply chain shifts. Financially, Aragen reported total income of Rs 1,675 crore and EBITDA of Rs 450 crore in FY24, with profit after tax at Rs 160 crore; revenue from operations was Rs 1,657.6 crore (down from Rs 1,736.6 crore in FY23), and net profit Rs 160.1 crore. FY25 revenue is estimated at Rs 1,800 crore and PAT at Rs 220 crore. This investment positions Aragen for an IPO, with Quadria joining Goldman Sachs as a strategic investor to scale in the growing pharmaceutical outsourcing market.
Dec 2015SecondaryChrysCapital (lead)$25M--

Who has invested in Aragen Life Sciences?

4 investors have backed Aragen Life Sciences across its funding rounds, including ChrysCapital, Quadria Capital, Avendus Capital and SBI Life Insurance.

Lead investors include Avendus Capital, SBI Life Insurance, Quadria Capital and ChrysCapital.


Aragen Life Sciences Investors

Investors in Aragen Life Sciences by funding rounds participated
InvestorHQRoundsRoleFirst check
Avendus CapitalUnited StatesNew York City, NY1LeadAug 2025
SBI Life InsuranceJapanTokyo1LeadAug 2025

This data is available for Pro users. Sign up to see all 4 Aragen Life Sciences investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Acquisitions by Aragen Life Sciences

Aragen Life Sciences has acquired 3 companies to date.

Last acquisition by Aragen Life Sciences was on December 15th 2021. Aragen Life Sciences acquired Intox for undisclosed valuation.


Latest Acquisitions by Aragen Life Sciences

Intox
Vanta Bioscience
Aragen Bioscience
Description
Intox is a Czech Republic-based contract research organization offering in vivo and in vitro toxicology studies. The Prague-headquartered lab conducts safety assessments, genotoxicity tests, and ecotoxicology for agrochemicals, pharmaceuticals, and consumer products. Intox supports regulatory submissions under OECD and GLP standards with facilities for acute, subchronic, and reproductive toxicity. Its services extend to analytical chemistry and histopathology.
Vanta Bioscience Ltd is a full-service preclinical contract research organization based in Chennai, India, providing preclinical safety assessment services for the pharmaceutical, medical devices, nutraceuticals, biotech, agrochemicals, cosmetics, chemical, and feed additive industries. Established as a center of excellence in GLP-compliant toxicology and safety assessment, the company supports clients through toxicology studies, batch release tests, biocompatibility evaluations, agro-chemical and chemical safety assessments, and diet formulation services. It also offers testing and contract research services in clinical and pre-clinical research, biopharma studies, analytical testing, and environmental assessments.
Aragen Bioscience is a Morgan Hill-headquartered contract research organization delivering preclinical services including recombinant cell line development, protein production, assay development, and in vivo models for pharmaceutical and biotech clients. Based in California since its founding in 2006, the company operates a 50,000-square-foot facility supporting hybridoma generation and immunological assays for drug discovery programs.
HQ CountryIndiaIndiaUnited States
HQ City
Pune
-
San Jose, CA
Deal Date15 Dec 20216 Nov 201429 Jan 2014
Valuationundisclosedundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Aragen Life Sciences acquisitions and their M&A valuation multiples.

Start Free Trial

Aragen Life Sciences Competitors

Aragen Life Sciences competitors include listed companies like Syngene, Anupam Rasayan India and ST Pharm, and private ones like VectorBuilder, Safe Medical Evaluation and Sangon Biotech.

Public and private companies comparable to Aragen Life Sciences
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
SyngeneIndiaIndiaPublicly listed$376M$88M$1.6B3.9x
VectorBuilderUnited StatesChicago, ILPrivate--$1B-
Safe Medical EvaluationChinaBeijingPrivate--$574M-
Sangon BiotechChinaShanghaiPrivate$102M-$1.4B13.7x
Anupam Rasayan IndiaIndiaIndiaPublicly listed$242M$55M$1.4B6.9x
ST PharmSouth KoreaSouth KoreaPublicly listed$241M$65M$1.4B4.7x

Aragen Life Sciences Public Comps

Aragen Life Sciences is still privately-owned, but its public comps include Anupam Rasayan India, ST Pharm, Sansure Biotech, VCANBIO, Akums Drugs and Pharma, Absci, Syngene, Vazyme Biotech, Aurisco Pharmaceutical and Jubilant Pharmova.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Anupam Rasayan India$242M$55M7.0x6.9x31.1x28.8x
ST Pharm$241M$65M5.5x4.7x20.4x17.8x
Sansure Biotech$245M$48M4.2x4.1x21.3x14.6x
VCANBIO$217M$44M4.6x4.3x22.8x25.1x
Akums Drugs and Pharma$443M$54M2.4x2.2x19.9x16.6x
Absci$3M($103M)496.8x388.4x(13.5x)(11.9x)
Syngene$376M$88M4.0x3.9x17.1x15.5x
Vazyme Biotech$205M$18M6.6x6.0x76.5x35.0x

This data is available for Pro users. Sign up to see all Aragen Life Sciences competitors and their valuation data.

Start Free Trial

Common questions about Aragen Life Sciences

When was Aragen Life Sciences founded?Aragen Life Sciences was founded in 2001.
Where is Aragen Life Sciences headquartered?Aragen Life Sciences is headquartered in Hyderabad, India.
Is Aragen Life Sciences publicly listed?No, Aragen Life Sciences is a private, VC-backed company.
What is Aragen Life Sciences' valuation?Aragen Life Sciences was last valued at $1.4B in its undisclosed-stage round in January 2025.
How much funding has Aragen Life Sciences raised?Aragen Life Sciences has raised $100M across 1 funding round.
What was Aragen Life Sciences' last funding round?Aragen Life Sciences' last funding round was a $100M undisclosed-stage round in January 2025, led by Quadria Capital.
Who are Aragen Life Sciences' investors?Aragen Life Sciences' investors include Avendus Capital, SBI Life Insurance, Quadria Capital and ChrysCapital.
What is Aragen Life Sciences' revenue?Aragen Life Sciences' latest recorded revenue is $179M (January 2025).
What is Aragen Life Sciences' revenue multiple?Aragen Life Sciences' latest valuation implies a 7.8x revenue multiple ($1.4B valuation on $179M of revenue).
Which companies are comparable to Aragen Life Sciences?Companies comparable to Aragen Life Sciences include Syngene, VectorBuilder, Safe Medical Evaluation, Sangon Biotech, Anupam Rasayan India and ST Pharm.
How many companies has Aragen Life Sciences acquired?Aragen Life Sciences has acquired 3 companies, including Intox, Vanta Bioscience and Aragen Bioscience.

See companies similar to Aragen Life Sciences

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial